



May 12, 2022

Scope Guide updated 5/12/2022

Dear Provider:

DHCS has announced that beginning 6/1/2022, blood pressure monitors will now be processed through MCRx. KFHC would like to remind providers where to submit prior authorization requests and who should be billed for services provided/rendered.

If a prior authorization is needed for the following services, please submit to <u>Magellan</u> (PBM vendor for MCRx). The billing of the services should also be to <u>Magellan</u> for dates of service beginning 6/1/2022:

Outpatient MedicationsVaccinesEnteralsCondomsDiaphragmsCervical CapsPeak Flow MetersAerochambersAll SyringesPen NeedlesDiabetic Test StripsLancets

Continuous Glucose Monitor/Supplies Disposable Insulin Delivery Devices (Omnipod/VGo {pumps})

Over the Counter EUA (Emergency Use Authorization) COVID-19 Antigen Tests

Blood Pressure Machines

The Payer Sheet information for Magellan is [BIN: 022659, PCN: 6334225]

In addition to all outpatient pharmacy/medication claims with a date of service prior to 1/1/2022, the following services will remain with KFHC. Please be sure to include the appropriate ICD-10 code for each service billed. After the transition to MCRx, the following services will continue to be billed through KFHC's PBM (SS&C) as they are today. [SS&C BIN: 600428, PCN: 04970000, Group: not required/blank]

Incontinence Supplies Ostomy Supplies Crutches/canes
Thermometers Hand Sanitizer T.E.D. Hose

Nebulizers & Supplies Tablet Cutter Braces (wrist/ankle/back/neck)

We know this is a big endeavor. More information regarding the MCRx program can be found at the MCRx website, https://medi-calrx.dhcs.ca.gov/home/. KHS has posted valuable information received from the DHCS on the KHS website regarding the transition. Please visit www.kernfamilyhealthcare.com.

We appreciate your cooperation as we work together through this transition. We want to thank you again for the valuable service you provide to our members. If you have any questions, please contact your Provider Relations Representative.

Sincerely,

Bruce Wearda, R.Ph. Director of Pharmacy